Literature DB >> 30837214

High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant.

Johanna Gebhart1, Florian Posch1,2, Silvia Koder1, Peter Quehenberger3, Thomas Perkmann3, Lorenz Kuessel4, Cihan Ay1, Ingrid Pabinger1.   

Abstract

Lupus anticoagulant (LA) has been associated with pregnancy complications and pregnancy loss. Identification of predictive factors could aid in deciding on therapeutic management. To identify risk factors for adverse pregnancy outcomes in high-risk women with persistently positive LA, we prospectively followed 82 women of childbearing age, of whom 23 had 40 pregnancies within the Vienna Lupus Anticoagulant and Thrombosis Study. Pregnancy complications occurred in 28/40 (70%) pregnancies, including 22 (55%) spontaneous abortions (<10th week of gestation [WOG]: n = 12, 10th to 24th WOG: n = 10) and 6 deliveries <34th WOG (15%, 3 due to severe preeclampsia/HELLP [hemolysis, elevated liver enzymes, and a low platelet count] syndrome, 3 due to placental insufficiency). One abortion was followed by catastrophic antiphospholipid syndrome. Neither a history of pregnancy complications nor of thrombosis, or prepregnancy antiphospholipid antibody levels were associated with adverse pregnancy outcomes. In logistic regression analysis, higher age was associated with a lower risk of adverse pregnancy outcome (per 5 years' increase: odds ratio [OR] = 0.41, 95% confidence interval [CI]: 0.19-0.87), a high Rosner index (index of circulating anticoagulant) predicted an increased risk (OR = 4.51, 95% CI: 1.08-18.93). Live birth rate was 15/28 (54%) in women on the combination of low-molecular-weight heparin and low-dose aspirin and 3/12 (25%) in those with no treatment or a single agent. We conclude that the risk of severe, even life-threatening pregnancy complications and adverse pregnancy outcomes is very high in women with persistent LA. A high Rosner index indicates an increased risk. Improved treatment options for women with persistently positive LA are urgently needed.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30837214      PMCID: PMC6418496          DOI: 10.1182/bloodadvances.2018026948

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  40 in total

1.  Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.

Authors:  Raj Rai; Lesley Regan
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

2.  Heparin and aspirin versus aspirin alone for prevention of recurrent pregnancy loss.

Authors:  Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

3.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

4.  Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the HepASA trial.

Authors:  Howard J A Carp
Journal:  J Rheumatol       Date:  2010-01       Impact factor: 4.666

5.  Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome.

Authors:  A Ruffatti; A Calligaro; A Hoxha; D Trevisanuto; A T Ruffatti; M T Gervasi; S Cuffaro; V Pengo; L Punzi
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-03       Impact factor: 4.794

Review 6.  Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study.

Authors:  Arsène Mekinian; Jaume Alijotas-Reig; Fabrice Carrat; Nathalie Costedoat-Chalumeau; Amelia Ruffatti; Maria Grazia Lazzaroni; Sara Tabacco; Aldo Maina; Agathe Masseau; Nathalie Morel; Enrique Esteve Esteve-Valverde; Raquel Ferrer-Oliveras; Laura Andreoli; Sara De Carolis; Laurence Josselin-Mahr; Noémie Abisror; Pascale Nicaise-Roland; Angela Tincani; Olivier Fain
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

7.  Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.

Authors:  Roy G Farquharson; Siobhan Quenby; Michael Greaves
Journal:  Obstet Gynecol       Date:  2002-09       Impact factor: 7.661

8.  Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed.

Authors:  Laura E J Peeters; Els Daeseleire; Mathias Devreese; Geertrui Rasschaert; Annemieke Smet; Jeroen Dewulf; Marc Heyndrickx; Hein Imberechts; Freddy Haesebrouck; Patrick Butaye; Siska Croubels
Journal:  BMC Vet Res       Date:  2016-09-20       Impact factor: 2.741

9.  Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

Authors:  G R de Jesús; S Sciascia; D Andrade; M Barbhaiya; M Tektonidou; A Banzato; V Pengo; L Ji; P L Meroni; A Ugarte; H Cohen; D W Branch; L Andreoli; H M Belmont; P R Fortin; M Petri; E Rodriguez; R Cervera; J S Knight; T Atsumi; R Willis; I S Nascimento; R Rosa; D Erkan; R A Levy
Journal:  BJOG       Date:  2018-10-24       Impact factor: 6.531

10.  Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies.

Authors:  Micaela Fredi; Laura Andreoli; Elena Aggogeri; Elisa Bettiga; Maria Grazia Lazzaroni; Véronique Le Guern; Andrea Lojacono; Nathalie Morel; Jean Charles Piette; Sonia Zatti; Nathalie Costedoat-Chalumeau; Angela Tincani
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

View more
  3 in total

Review 1.  Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review.

Authors:  Pavla Bradacova; Ludek Slavik; Jana Ulehlova; Adela Skoumalova; Jana Ullrychova; Jana Prochazkova; Antonin Hlusi; Gayane Manukyan; Eva Kriegova
Journal:  Biomedicines       Date:  2021-02-08

2.  Reference intervals for coagulation parameters in non-pregnant and pregnant women.

Authors:  Mengyu Fu; Junjie Liu; Jinfang Xing; Yanpeng Dai; Yanzi Ding; Kainan Dong; Xuewei Zhang; Enwu Yuan
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.996

3.  Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome.

Authors:  Pavla Bradáčová; Luděk Slavík; Adéla Skoumalová; Jana Úlehlová; Eva Kriegová; Gayane Manukyan; David Friedecký; Barbora Piskláková; Jana Ullrychová; Jana Procházková; Antonín Hluší
Journal:  Int J Mol Sci       Date:  2022-08-11       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.